摘要
目的观察咪唑立宾（MZR）预防肾移植后排斥反应的效果及不良反应。方法100例肾移植患者后采用由MZR与环孢素A（CsA）、泼尼松（Pred）组成的三联方案预防排斥反应（MZR组），以100例采用CsA、霉酚酸酯（MMF）与Pred组合者为对照（MMF组），随访12个月，观察急性排斥反应发生率，人、肾存活率以及与药物有关的不良反应。结果术后12个月内，MZR组及MMF组急性排斥反应发生率分别为11％和9％，差异无统计学意义。MZR组人、肾存活率均为100％，MMF组均为99％。MZR组腹泻、严重肺部感染的发生率分别为4％和1％，明显低于MMF组的12％和6％，而血尿酸升高者（25％）明显多于MMF组（6％），差异均有统计学意义（P〈0．05）。结论含咪唑立宾的免疫抑制方案用于预防肾移植后的排斥反应安全、有效，不良反应较少。
Objective To observe the efficacy and side effect of mizoribine to prevente rejection after renal transplantation. Methods 100 primary kidney transplant recipients in MZR group were treated with triple therapy including mizorihine, cyclosporine （CsA） and prednisone （Pred）. As controls, the other 100 patients （MMF group） were administrated with mycophenolate mofifile （MMF） instead of MZR combined with CsA and Pred. During the follow-up period of 12 months, the incidence of acute rejection, patient/graft survival and adverse effects associated with drugs in two groups were observed. Results There was no significant difference in incidence of acute rejection between MZR group （11%） and MMF group（9%）. The patient/graft survival in MZR group was 100%, while 99% in MMF group. The incidence of diarrhea and severe pulmonary infection in MZR group was 4% and 1%, which was lower than MMF group （12% and 6%） significantly. There was significant difference in the incidence of hyperuricacidemia between MZR group （25 % ） and MMF group （6 % ） （P 〈0. 05 ）. Conclusion Immunosuppressive therapy including mizoribine can prevent acute rejection after kidney transplantation effectively and safely.
出处
《中华器官移植杂志》
CAS
CSCD
北大核心
2008年第1期14-15,共2页
Chinese Journal of Organ Transplantation
关键词
肾移植
免疫抑制剂
免疫抑制法
Kidney transplantation
Irnmunosuppressive agents
Immunosuppression
